NSECredit Rating1d ago · 17 Nov 2026, 07:30 pm

Credit Rating

Thirumalai Chemicals Limited · TIRUMALCHM

✦ AI SummaryRating Change

Thirumalai Chemicals Limited has informed the Exchange about Credit Rating. ICRA notes the improvement in consolidated profitability in H1FY2027, with operating profit increasing to Rs. 71.2 crore compared to the preceding losses, owing to improvement in PAN-OX spreads. However, the coverage indicators remain under pressure and sustained improvement in profitability remains a key monitorable going forward.

Analysis Scores

Earnings Impact6/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk4/10
Balance Sheet Risk7/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Thirumalai Chemicals Limited has informed the Exchange about Credit Rating

Attachments (1)

📄

TIRUMALCHM1_17112026192906_SELetterCreditRatingletter17112026SD.pdf

pdf

Download →
View document text
Registered Office: “THIRUMALAI HOUSE”, Plot No. 101-102, Road No. 29, Sion (East), Mumbai – 400 022, India PHONE: +91 – 22– 43686200 FAX +91 – 22 – 24011699 E- MAIL: thirumalai@thirumalaichemicals.com Website: www.thirumalaichemicals.com (AN ISO 9001, 14001, 50001/ HACCP & FSSC 22000 CERTIFIED COMPANY) CIN: L24100MH1972PLC016149 TCL/SE061/2026-27 November 17, 2026 The National Stock Exchange of India Ltd. BSE Limited Listing Department Department of Corporate Services Exchange Plaza, Bandra Kurla Complex Floor 25, Phiroze Jeejeebhoy Towers Bandra (East) Dalal Street Mumbai 400 051 Mumbai 400 001 Scrip code: TIRUMALCHM Scrip code: 500412 Dear Sir/ Madam, Sub.: Sub: Intimation under Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Credit Rating Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Regulations”), we inform you of the rating action, based on the intimation received from ICRA Limited dated November 16, 2026, as summarized below: Instrument Previous Current Rating Action Reason / Rated Rated Rationale Amount Amount (Rs. In cr.) (Rs. In cr.) Long term - Fund 445.00 445.00 [ICRA]BBB based - Term loan (Negative) Long term Fund based 334.50 334.50 [ICRA]BBB -Working capital (Negative) facilities Reaffirmed – Short term –Non-fund- (684.00) (755.00) [ICRA]A3+ based Facilities Letter Long term/Short term - 350.00 275.00 [ICRA]BBB Attached Unallocated limits (Negative) Short term –Non-fund- 175.00 175.00 [ICRA]A3+ based Facilities Non-convertible 100.00 100.00 [ICRA]BBB debentures (Negative); Registered Office: “THIRUMALAI HOUSE”, Plot No. 101-102, Road No. 29, Sion (East), Mumbai – 400 022, India PHONE: +91 – 22– 43686200 FAX +91 – 22 – 24011699 E- MAIL: thirumalai@thirumalaichemicals.com Website: www.thirumalaichemicals.com (AN ISO 9001, 14001, 50001/ HACCP & FSSC 22000 CERTIFIED COMPANY) CIN: L24100MH1972PLC016149 Kindly take the above information in your records. Thanking you, Yours faithfully, For Thirumalai Chemicals Limited Aditya Sharma Company Secretary & Compliance officer Encl: As above November 16, 2026 Thirumalai Chemicals Limited: Update on Material Event Summary of rating action Previous rated Current rated Financial Sector Instrument* amount amount Rating outstanding Regulator# (Rs. crore) (Rs. crore) Long term - Fund based - 445.00 445.00 [ICRA]BBB(Negative) RBI Term loan Long term - Fund based - 334.50 334.50 [ICRA]BBB(Negative) RBI Working capital facilities Short term – Non-fund (684.00) (755.00) [ICRA]A3+ RBI based facilities Long term/Short term - 350.00 275.00 [ICRA]BBB(Negative)/[ICRA]A3+ RBI Unallocated limits Short term – Non-fund 175.00 175.00 [ICRA]A3+ RBI based facilities Non-convertible 100.00 100.00 [ICRA]BBB(Negative) MCA debentures Total 1,404.50 1329.50 *Instrument details are provided in Annexure I; # SEBI’s grievance redressal/dispute resolution and SEBI investor protection mechanisms such as SCORES and ODR shall not be available for activities and instruments which fall under the regulatory purview of Financial Sector Regulators other than SEBI. Rationale Material Event Thirumalai Chemicals Limited (TCL) announced its Q2FY2027 results on November 05, 2026. ICRA notes the improvement in consolidated profitability in H1FY2027, with operating profit increasing to Rs. 71.2 crore compared to the preceding losses, owing to improvement in PAN-OX spreads. However, the coverage indicators remain under pressure and sustained improvement in profitability remains a key monitorable going forward. ICRA takes note of the various refinancing options under consideration by the company to reduce the pressure on coverage metrics and improve liquidity. The overall liquidity profile is expected to be supported by refinancing initiatives, other divestments, and operational cash flows. The timely refinancing of the loan for US project remains a key rating sensitivity and monitorable. Additionally, the full commissioning and subsequent ramp-up of the US project, TCL Specialties LLC, will remain a key monitorable over the near to medium term. Upon stabilisation, the project is expected to improve the company’s product mix and geographical diversification, supporting an expansion in operating margins. Please refer to the following link for the previous detailed rationale, which covers the key rating drivers and their descriptions, liquidity position, and rating sensitivities. Click here. www. icra .in Page | Sensitivity Label : Public Analytical approach Analytical Approach Comments Corporate Credit Rating Methodology Applicable rating methodologies Chemicals Parent/Group support Not applicable The ratings are based on the consolidated financial profile of the company. The details of the Consolidation/Standalone consolidation are provided in Annexure II About the company TCL started its operations in 1976 at Ranipet in Tamil Nadu as a single product petrochemical company, manufacturing phthalic anhydride (PAN), with a production capacity of 6,000 TPA. Over the years, TCL has expanded its total PAN manufacturing capacity to ~1,72,000 TPA, including Dahej phase 1, and has added other products to its portfolio, which includes food additives such as Malic acid and Fumaric acid, and PAN derivatives such as Di-ethyl phthalate (DEP) and Phthalimide (PID). In FY2025, the Dahej phase II project was commissioned which added ~96,000-TPA capacity of PAN and ~10,000 TPA of fumaric acid. TCL caters to customers in the construction, auto, paint, food, personal care and pharmaceutical industries. It also has a maleic anhydride (MAN) manufacturing facility in Malaysia under its step-down subsidiary, Optimistic Organic Sdn. Bhd, which is largely non-operational. (OOSB). The company is also expected to fully commence its US project in Q4FY2027, which is a facility for manufacturing MAN and food acids. Key financial indicators TCL Consolidated FY2025 FY2026 H1 FY2027* Operating income 2,051.4 1,735.5 1,143.1 PAT -46.1 -167.9 -78.0 OPBDIT/OI 2.7% -1.4% 6.2% PAT/OI -2.2% -9.7% -6.8% Total outside liabilities/Tangible net worth (times) 2.3 2.0 2.3 Total debt/OPBDIT (times) 32.1 -91.3 15.6 Interest coverage (times) 1.1 -0.3 0.7 Source: Company, ICRA Research; All ratios as per ICRA’s calculations; Amount in Rs. Crore; PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation; Amount in Rs. crore; *Results Status of non-cooperation with previous CRA: Not applicable Any other information: None www. icra .in Page | Sensitivity Label : Public Rating history for past three years Chronology of rating history Current rating (FY2027) for the past 3 years Date & rating in FY2026 Date & rating in Date & rating in FY2027 Date & rating in FY2025 Instru- Amount FY2024 ment Type rated November Jan 12, Nov 25, August 13, June 09, Aug 26, May 27, Feb 14, Aug 04, (Rs. crore) 16, 2026 2025 Dec 03, 2024 May 24, 2024 2026 2026 2025 2025 2024 2023 2026 Term Long [ICRA]BBB [ICRA]BBB [ICRA]BBB+ [ICRA]BBB+ [ICRA]A [ICRA]A+ [ICRA]A+ [ICRA]A+ 1 445.00 (Nega- (Nega- (Nega- loans term (Negative) (Negative) (Negative) (Negative) (Negative) (Negative) (Negative) (Stable) tive) tive) tive) Fund [ICRA]A- [ICRA]A- [ICRA]A+ Long [ICRA]BBB [ICRA]BBB [ICRA]BBB+ [ICRA]BBB+ [ICRA]A [ICRA]A+ [ICRA]A+ [ICRA]A+ 2 based lim- 334.50 (Nega- (Nega- (Nega- term (Negative) (Negative) (Negative) (Negative) (Negative) (Negative) (Negative) (Stable) its tive) tive) tive) Non-fund Short 3 based fa- 175.00 [ICRA]A3+ [ICRA]A3+ [ICRA]A2 [ICRA]A2 [ICRA]A2+ [ICRA]A2+ [ICRA]A2+ - - - - term cilities Long [ICRA]BBB+ [ICRA]BBB+ [ICRA]A- [ICRA]A- [ICRA]BBB [ICRA]BBB [ICRA]A(Neg- [ICRA]A+(Neg- [ICRA]A+(Neg- Unallo- term/ (Negative) (Negative) (Nega- (Nega- 4 275.00 (Negative)/ (Negative)/ ative)/ ative)/ ative)/ - - cated Short / / tive) / tive) / term [ICRA]A2 [ICRA]A2 [ICRA]A2+ [ICRA]A2+ Non-fund based fa- Sh [Showing first 8,000 characters — download PDF for full document]